B-cell lymphoma/leukemia 10 (Bcl10) and angiotensin II-induced kidney injury.
暂无分享,去创建一个
F. Luft | J. Ruland | S. Rong | S. Forslund | A. Balogh | L. Markó | R. Dechend | D. Müller | Joon-Keun Park | H. Bartolomaeus | N. Wilck | N. Henke | Samuel Klamer
[1] T. B. Huber,et al. The Evolving Complexity of the Podocyte Cytoskeleton. , 2017, Journal of the American Society of Nephrology : JASN.
[2] Wei-wei Wang,et al. The mTORC2/Akt/NFκB Pathway-Mediated Activation of TRPC6 Participates in Adriamycin-Induced Podocyte Apoptosis , 2016, Cellular Physiology and Biochemistry.
[3] J. Becker,et al. Live or Let Die: Is There any Cell Death in Podocytes? , 2016, Seminars in nephrology.
[4] K. Homma,et al. Podocyte-specific NF-κB inhibition ameliorates proteinuria in adriamycin-induced nephropathy in mice , 2016, Clinical and Experimental Nephrology.
[5] D. Harrison,et al. Inflammation, immunity, and hypertensive end-organ damage. , 2015, Circulation research.
[6] P. Lucas,et al. Bcl10 Mediates Angiotensin II–Induced Cardiac Damage and Electrical Remodeling , 2014, Hypertension.
[7] D. Harrison,et al. DC isoketal-modified proteins activate T cells and promote hypertension. , 2014, The Journal of clinical investigation.
[8] L. Navar,et al. The absence of intrarenal ACE protects against hypertension. , 2013, The Journal of clinical investigation.
[9] F. Thaiss,et al. Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria. , 2012, American journal of physiology. Renal physiology.
[10] J. Ruland,et al. The NF-κB signaling protein Bcl10 regulates actin dynamics by controlling AP1 and OCRL-bearing vesicles. , 2012, Developmental cell.
[11] F. Luft,et al. Immune mechanisms in angiotensin II-induced target-organ damage , 2012, Annals of medicine.
[12] P. Lucas,et al. From MALT lymphoma to the CBM signalosome , 2011, Cell cycle.
[13] T. Coffman,et al. AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. , 2011, Cell metabolism.
[14] R. Schmieder. End organ damage in hypertension. , 2010, Deutsches Arzteblatt international.
[15] P. Lucas,et al. Thrombin-dependent NF-κB Activation and Monocyte/Endothelial Adhesion Are Mediated by the CARMA3·Bcl10·MALT1 Signalosome* , 2010, The Journal of Biological Chemistry.
[16] P. Lucas,et al. The CARMA3-Bcl10-MALT1 Signalosome Promotes Angiotensin II-dependent Vascular Inflammation and Atherogenesis* , 2010, The Journal of Biological Chemistry.
[17] Hyung-Suk Kim,et al. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[18] J. Gutkind,et al. CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) Complex* , 2009, Journal of Biological Chemistry.
[19] D. Harrison,et al. Is hypertension an immunologic disease? , 2008, Current cardiology reports.
[20] M. Zenke,et al. Novel Role for Inhibitor of Differentiation 2 in the Genesis of Angiotensin II–Induced Hypertension , 2008, Circulation.
[21] D. Harrison,et al. Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction , 2007, The Journal of experimental medicine.
[22] R. Dietz,et al. Vascular Endothelial Cell–Specific NF-&kgr;B Suppression Attenuates Hypertension-Induced Renal Damage , 2007, Circulation research.
[23] D. Krappmann,et al. CARD-Bcl10-Malt1 Signalosomes: Missing Link to NF-κB , 2007, Science's STKE.
[24] T. Mak,et al. Bcl10 Controls TCR- and FcγR-Induced Actin Polymerization1 , 2007, The Journal of Immunology.
[25] S. Eguchi,et al. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. , 2007, Clinical science.
[26] T. Mak,et al. CARMA3/Bcl10/MALT1-dependent NF-κB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells , 2007, Proceedings of the National Academy of Sciences.
[27] Phillip Ruiz,et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney , 2006, Proceedings of the National Academy of Sciences.
[28] T. Gilmore. Introduction to NF-κB: players, pathways, perspectives , 2006, Oncogene.
[29] A. Kribben,et al. CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking. , 2006, Journal of the American Society of Nephrology : JASN.
[30] J. Egido,et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[31] N. Gretz,et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. , 2004, Journal of the American Society of Nephrology : JASN.
[32] Matthias Kretzler,et al. Cell biology of the glomerular podocyte. , 2003, Physiological reviews.
[33] F. Luft,et al. Endothelin-Converting Enzyme Inhibition Ameliorates Angiotensin II–Induced Cardiac Damage , 2002, Hypertension.
[34] M. Zenke,et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. , 2002, The American journal of pathology.
[35] David Baltimore,et al. CARD11 mediates factor‐specific activation of NF‐κB by the T cell receptor complex , 2002, The EMBO journal.
[36] G. Viberti,et al. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.
[37] J. Tschopp,et al. CARMA1 is a critical lipid raft–associated regulator of TCR-induced NF-κB activation , 2002, Nature Immunology.
[38] J. Bertin,et al. A requirement for CARMA1 in TCR-induced NF-κB activation , 2002, Nature Immunology.
[39] F. Thaiss,et al. Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors11See Editorial by Luft, p. 2272. , 2002 .
[40] F. Thaiss,et al. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. , 2002, Kidney international.
[41] T. Sugaya,et al. Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. , 2002, Journal of the American Society of Nephrology : JASN.
[42] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[43] D. Harrison,et al. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. , 2002, Circulation.
[44] J. Egido,et al. Angiotensin II and renal fibrosis. , 2001, Hypertension.
[45] Yusuke Suzuki,et al. Proinflammatory actions of angiotensins , 2001, Current opinion in nephrology and hypertension.
[46] T. Mak,et al. Bcl10 Is a Positive Regulator of Antigen Receptor–Induced Activation of NF-κ B and Neural Tube Closure , 2001, Cell.
[47] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[48] D. Ganten,et al. NF-κB Inhibition Ameliorates Angiotensin II–Induced Inflammatory Damage in Rats , 2000 .
[49] D. Ganten,et al. Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.
[50] L. Raij,et al. Angiotensin II, nitric oxide, and end-organ damage in hypertension. , 1998, Kidney international. Supplement.
[51] E. Fleck,et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. , 1997, Circulation research.